Compagnie Lombard Odier SCmA’s NeuBase Therapeutics, Inc. Common Stock NBSE Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2020
Q3 | – | Sell |
-14
| Closed | -$3K | – | 591 |
|
|
2020
Q2 | $3K | Hold |
14
| – | – | ﹤0.01% | 498 |
|
|
2020
Q1 | $2K | Buy |
14
+4
| +40% | +$571 | ﹤0.01% | 476 |
|
|
2019
Q4 | $1K | Hold |
10
| – | – | ﹤0.01% | 506 |
|
|
2019
Q3 | $1K | Hold |
10
| – | – | ﹤0.01% | 511 |
|
|
2019
Q2 | $1K | Hold |
10
| – | – | ﹤0.01% | 506 |
|
|
2019
Q1 | $0 | Hold |
10
| – | – | ﹤0.01% | 602 |
|
|
2018
Q4 | $0 | Hold |
10
| – | – | ﹤0.01% | 597 |
|
|
2018
Q3 | $1K | Hold |
10
| – | – | ﹤0.01% | 535 |
|
|
2018
Q2 | $1K | Hold |
10
| – | – | ﹤0.01% | 571 |
|
|
2018
Q1 | $1K | Sell |
10
-10
| -50% | -$1K | ﹤0.01% | 578 |
|
|
2017
Q4 | $14K | Buy |
20
+10
| +100% | +$7K | ﹤0.01% | 581 |
|
|
2017
Q3 | $3K | Hold |
10
| – | – | ﹤0.01% | 657 |
|
|
2017
Q2 | $3K | Hold |
10
| – | – | ﹤0.01% | 681 |
|
|
2017
Q1 | $3K | Hold |
10
| – | – | ﹤0.01% | 697 |
|
|
2016
Q4 | $6K | Hold |
10
| – | – | ﹤0.01% | 769 |
|
|
2016
Q3 | $11K | Hold |
10
| – | – | ﹤0.01% | 832 |
|
|
2016
Q2 | $11K | Hold |
10
| – | – | ﹤0.01% | 823 |
|
|
2016
Q1 | $13K | Hold |
10
| – | – | ﹤0.01% | 863 |
|
|
2015
Q4 | $25K | Sell |
10
-10
| -50% | -$25K | ﹤0.01% | 771 |
|
|
2015
Q3 | $22K | Hold |
20
| – | – | ﹤0.01% | 686 |
|
|
2015
Q2 | $20K | Buy |
+20
| New | +$20K | ﹤0.01% | 720 |
|